Immuno-oncology – Endpoints News

Ticker	Current Price	Change	Graph
IBB	102.80	2.25 (2.14%)
XBI	76.91	2.61 (3.28%)

Seeking an edge in the global I/O race, Alphamab Oncology loads up $100M-plus from marquee backers

by Amber Tong — on November 19, 2018 08:23 AM EST
Updated: 08:39 AM

Pfizer, Merck KGaA report their latest setback with checkpoint contender Bavencio

by John Carroll — on November 19, 2018 07:53 AM EST
Updated: 08:11 AM

The sandbox: Parker Institute throws its research muscle behind gene therapy tech for destroying cancer cells

by John Carroll — on November 15, 2018 10:00 AM EST

On the heels of an Eli Lilly deal, NextCure’s hot hand in I/O attracts a $93M trans-Pacific venture round

by John Carroll — on November 13, 2018 06:31 AM EST
Updated: 10:02 AM

Innovent, Eli Lilly cite a new success for their PD-1 in lung cancer, with a likely pioneering approval in China looming

by John Carroll — on November 9, 2018 08:06 AM EST
Updated: 08:17 AM

Gilead throws its weight — and $50M cash — behind Tango’s I/O discovery engine

by Amber Tong — on October 31, 2018 08:58 AM EST
Updated: 11:15 AM

AstraZeneca is paying Innate Pharma at least $242M in near-term cash to sew up rights to monalizumab-plus

by John Carroll — on October 23, 2018 01:59 AM EST
Updated: 04:00 AM

Merck previews an early hit with Keytruda combo for kidney cancer, putting more pressure on rival Bristol-Myers

by John Carroll — on October 19, 2018 06:19 AM EST

SQZ play: Roche doubles down on a $1.37B-plus deal for a new approach to immuno-oncology out of Bob Langer’s lab

by John Carroll — on October 15, 2018 08:30 AM EST

Bristol-Myers concedes a PhIII lung cancer flop for Opdivo as competition heats up in SCLC

by John Carroll — on October 12, 2018 08:56 AM EST
Updated: 10:29 AM

Bristol-Myers embraces a possible checkpoint collaborator, snagging a batch of stock and lining up a potential deal

by John Carroll — on October 11, 2018 10:31 AM EST

Checkpoint therapies before surgery? MD Anderson team reports encouraging efficacy but worries about toxicity

by Amber Tong — on October 9, 2018 09:30 AM EST
Updated: 09:40 AM

Merck’s cancer R&D juggernaut ties up to little Dragonfly’s natural born killer platform — with billions on the line

by John Carroll — on October 1, 2018 08:59 AM EST

Cancer R&D stars Jim Allison, Tasuku Honjo awarded Nobel prize for immunotherapy discoveries

by Amber Tong — on October 1, 2018 07:16 AM EST
Updated: 07:46 AM

Ex-Kerrisdale analyst sets out to torpedo Nektar with a blunt short attack on star drug NKTR-214: ‘It doesn’t work’

by John Carroll — on October 1, 2018 06:00 AM EST
Updated: 10:42 AM

New York cancer center launches ‘historic’ JV to bring Cuban-developed cancer drugs to US

by Amber Tong — on September 27, 2018 10:09 AM EST
Updated: 04:38 PM

Roche’s IMpower133 offers a glimpse at rare progress in fight against small cell lung cancer

by John Carroll — on September 25, 2018 09:43 AM EST

AstraZeneca spells out a major drop in the risk of death for stage 3 NSCLC patients taking Imfinzi — and why that’s important

by John Carroll — on September 25, 2018 08:15 AM EST
Updated: 08:56 AM

Boehringer Ingelheim joins the crowd and goes all-in on oncolytic viruses, buying ViraTherapeutics in $244M deal

by John Carroll — on September 13, 2018 06:31 AM EST

Bristol-Myers will sell Opdivo in China at half of US cost, setting precedent for checkpoint wave — report

by Amber Tong — on August 22, 2018 08:44 AM EST
Updated: 01:34 PM

Category: Immuno-oncology